{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:32:08Z","timestamp":1792150328694,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bbrc.2016.07.114","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T21:30:29Z","timestamp":1469741429000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)"],"prefix":"10.1016","volume":"478","author":[{"given":"Hyun Tae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunju","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Yeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2016.07.114_bib1","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","article-title":"Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis ankylosing spondylitis","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2016.07.114_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2165\/00003495-200969110-00008","article-title":"Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2016.07.114_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00003495-199958030-00016","article-title":"Rofecoxib","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2016.07.114_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/13543776.12.7.969","article-title":"Advances in the field of COX-2 inhibition","volume":"12","author":"de Leval","year":"2002","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bbrc.2016.07.114_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14740338.4.3.491","article-title":"The safety of rofecoxib","volume":"4","author":"Burnier","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bbrc.2016.07.114_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2174\/1389557043403792","article-title":"COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents","volume":"4","author":"Supuran","year":"2004","journal-title":"Mini. Rev. Med. Chem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/clpt.2012.3","article-title":"Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649","volume":"91","author":"Skarke","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2016.07.114_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2016.07.114_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/13543776.10.5.575","article-title":"Carbonic anhydrase inhibitors and their therapeutic potential","volume":"10","author":"Supuran","year":"2000","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bbrc.2016.07.114_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10025","article-title":"Carbonic anhydrase inhibitors","volume":"23","author":"Supuran","year":"2003","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbrc.2016.07.114_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/138161208783877866","article-title":"The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents","volume":"14","author":"Mincione","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbrc.2016.07.114_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bmcl.2003.09.063","article-title":"Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosyl-amines as topically acting antiglaucoma agents in hypertensive rabbits","volume":"14","author":"Winum","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2016.07.114_bib13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archopht.1988.01060140350030","article-title":"Treatment of chronic macular edema with acetazolamide","volume":"106","author":"Cox","year":"1988","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.bbrc.2016.07.114_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/jm030912m","article-title":"Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition","volume":"47","author":"Weber","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bmcl.2005.09.040","article-title":"Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II \u2018selective\u2019 inhibitor celecoxib","volume":"16","author":"Fiore","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2016.07.114_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2016.07.114_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collection in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Method. Enzymol."},{"key":"10.1016\/j.bbrc.2016.07.114_bib18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1107\/S0907444904009990","article-title":"Simple algorithm for a maximum-likelihood SAD function","volume":"60","author":"McCoy","year":"2004","journal-title":"Acta Crystlogr. D."},{"key":"10.1016\/j.bbrc.2016.07.114_bib19","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystlogr. D."},{"key":"10.1016\/j.bbrc.2016.07.114_bib20","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D."},{"key":"10.1016\/j.bbrc.2016.07.114_bib21","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1074\/jbc.M112.400754","article-title":"Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveals a highly convergent mechanism of divergent p53 pathways","volume":"288","author":"Ha","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1994.tb19909.x","article-title":"Inhibition and catalysis of carbonic anhydrase. Recent crystallographic analyses","volume":"15","author":"Liljas","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: chemistry, physiology, and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbrc.2016.07.114_bib24","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2016.07.114_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nature13302","article-title":"A\u00a0draft map of the human proteome","volume":"509","author":"Kim","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2016.07.114_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbrc.2016.07.114_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-007-0400-7","article-title":"Clinical use and pharmacological properties of selective COX-2 inhibitors","volume":"64","author":"Shi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2016.07.114_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-Selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bbrc.2016.07.114_bib29","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1073\/pnas.85.6.1962","article-title":"N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome","volume":"85","author":"Lewis","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2016.07.114_bib30","doi-asserted-by":"crossref","first-page":"47886","DOI":"10.1074\/jbc.M105959200","article-title":"A\u00a0transport metabolon. Functional interaction of carbonic anhydrase II and chloride\/bicarbonate exchangers","volume":"276","author":"Sterling","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib31","doi-asserted-by":"crossref","first-page":"36085","DOI":"10.1074\/jbc.M111952200","article-title":"Carbonic anhydrase II binds to and enhances activity of the Na+\/H+ exchanger","volume":"277","author":"Li","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2016.07.114_bib32","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1371\/journal.pone.0000839","article-title":"Blindness caused by deficiency in AE3 chloride\/bicarbonate exchanger","volume":"2","author":"Alvarez","year":"2007","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2016.07.114_bib33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1139\/y2012-142","article-title":"Carbonic anhydrase II promotes cardiomyocyte hypertrophy","volume":"90","author":"Brown","year":"2012","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbrc.2016.07.114_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cpdd.47","article-title":"GCG100649, a novel Cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I\/II: preliminary dose-exposure relationships to define clinical development strategies","volume":"2","author":"Hirankarn","year":"2013","journal-title":"Clin. Pharmocol. Drug Dev."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16312360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16312360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T04:27:55Z","timestamp":1541219275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16312360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0006291X16312360"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.114","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}